Anteris Technologies Ltd (ASX: AVR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Anteris Technologies Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Anteris Technologies Ltd (ASX: AVR)
Latest News
Healthcare Shares
2 ASX healthcare shares bucking the trend to hit new highs on Friday
Healthcare Shares
Anteris (ASX:AVR) share price soars 22% on successful human trial
Share Fallers
Why the Anteris (ASX:AVR) share price backtracked 6% today
Healthcare Shares
Why is the Anteris (ASX:AVR) share price surging today?
Share Market News
Anteris (ASX:AVR) share price drops 7% despite positive announcement
Share Market News
The Anteris (ASX:AVR) share price is down today but has soared 150% in 3 months
Share Market News
Why the Anteris Technologies (ASX:AVR) share price soared 23% today
Share Market News
Why the Anteris (ASX:AVR) share price will be on watch today
Share Market News
These 2 ASX healthcare shares popped today
Share Market News
Why the Anteris (ASX:AVR) share price is edging higher today
Record Highs
Twiggy Forrest backed Invex Therapeutics has now doubled since its IPO
Share Fallers
Why the Admedus share price is sinking again on more big losses
AVR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Anteris Technologies Ltd
Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The company derives key revenue from Australia and the U.S.
AVR Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
27 Mar 2024 | $23.20 | $0.75 | 3.34% | 5,973 | $22.60 | $23.20 | $22.60 |
26 Mar 2024 | $22.45 | $-0.05 | -0.22% | 17,073 | $22.20 | $22.93 | $22.10 |
25 Mar 2024 | $22.50 | $-0.44 | -1.92% | 17,414 | $22.93 | $22.93 | $22.20 |
22 Mar 2024 | $22.94 | $1.56 | 7.30% | 20,096 | $21.95 | $22.94 | $21.65 |
21 Mar 2024 | $21.38 | $0.65 | 3.14% | 16,130 | $20.85 | $21.51 | $20.85 |
20 Mar 2024 | $20.73 | $0.03 | 0.14% | 8,941 | $20.68 | $20.74 | $20.60 |
19 Mar 2024 | $20.70 | $0.09 | 0.44% | 7,168 | $20.80 | $20.80 | $20.61 |
18 Mar 2024 | $20.61 | $-0.19 | -0.91% | 6,392 | $20.75 | $20.75 | $20.55 |
15 Mar 2024 | $20.80 | $0.30 | 1.46% | 2,705 | $20.75 | $20.99 | $20.75 |
14 Mar 2024 | $20.50 | $-0.40 | -1.91% | 14,447 | $20.90 | $21.14 | $20.50 |
13 Mar 2024 | $20.90 | $0.90 | 4.50% | 209,761 | $20.00 | $21.00 | $20.00 |
12 Mar 2024 | $20.00 | $0.80 | 4.17% | 10,783 | $19.39 | $20.00 | $19.11 |
11 Mar 2024 | $19.20 | $0.19 | 1.00% | 9,161 | $19.00 | $19.20 | $18.90 |
08 Mar 2024 | $19.01 | $0.01 | 0.05% | 12,310 | $19.20 | $19.31 | $18.80 |
07 Mar 2024 | $19.00 | $0.20 | 1.06% | 23,771 | $18.90 | $19.30 | $18.75 |
06 Mar 2024 | $18.80 | $0.80 | 4.44% | 16,047 | $18.00 | $18.80 | $17.81 |
05 Mar 2024 | $18.00 | $0.60 | 3.45% | 14,415 | $17.40 | $18.00 | $17.40 |
04 Mar 2024 | $17.40 | $0.15 | 0.87% | 5,863 | $17.10 | $17.40 | $17.05 |
01 Mar 2024 | $17.25 | $0.25 | 1.47% | 6,813 | $17.00 | $17.25 | $16.95 |
29 Feb 2024 | $17.00 | $-0.50 | -2.86% | 10,534 | $17.00 | $17.20 | $16.90 |
28 Feb 2024 | $17.50 | $0.30 | 1.74% | 71,811 | $16.95 | $17.50 | $16.95 |
27 Feb 2024 | $17.20 | $0.00 | 0.00% | 12,719 | $17.20 | $17.20 | $16.86 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
15 Sep 2023 | Stephen (Steve) Denaro | Issued | 80,500 | $1,634,150 |
Issue of options.
|
15 Sep 2023 | John Seaberg | Issued | 157,500 | $3,197,250 |
Issue of options.
|
15 Sep 2023 | Wayne Paterson | Issued | 700,000 | $14,210,000 |
Issue of options.
|
15 Sep 2023 | Wenyi Gu | Issued | 80,500 | $1,634,150 |
Issue of options.
|
31 May 2023 | Wayne Paterson | Issued | 4,167 | $100,008 |
Issue of securities. As per announcement on 01-06-2023
|
31 May 2023 | Wayne Paterson | Issued | 4,167 | $99,174 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Stephen (Steve) Denaro | Company SecretaryNon-Executive Director | Oct 2018 |
Mr Denaro was appointed as Non-Executive Director and Company Secretary on 31 October 2018. Mr Denaro has more than 30 years of senior level and Board level experience across publiclylisted companies; serving as Chief Financial Officer, Company Secretary and Director. He brings experience in managing compliance with finance and accounting regulatory requirements. He has managed investment acquisitions and subsequent funding (domestic and international). Mr Denaro is a resident of Brisbane, QLD, Australia.
|
Mr John Seaberg | Non-Executive DirectorNon-Executive Chairman | Oct 2014 |
Mr Seaberg has been an independent Non-Executive Director of Anteris Technologies Ltd since 10 October 2014. He was appointed as Deputy Chair on 16 June 2016 and Chair on 14 March 2017. From 2008 until its sale to Baxter in 2012, Mr Seaberg served as Chair of the Board of Synovis Inc (NASDAQ:SYNO), a Minneapolis based manufacturer of various medical devices and bio scaffold tissue products. From 2007 until 2014 he was Founder, Chair and CEO of NeoChord Inc., a venture capital-backed company commercialising technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr Seaberg served at Guidant Corp (subsequently acquired by Boston Scientific Corp) where he served in various executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, Mr Seaberg was co-founder of ACIST Medical and served as its first President and CEO. Mr Seaberg is a resident of Minneapolis, Minnesota, United States of America. He is a member of Risk Management Committee.
|
Mr Wayne Paterson | Managing DirectorChief Executive Officer | Feb 2016 |
Mr Paterson has been a Director of Anteris Technologies Ltd since 10 October 2014. Mr Paterson has held numerous senior positions in multi-national pharmaceutical companies and has lived in seven countries during the past 20 plus years. Throughout his career, he has been responsible for building and managing multi-billion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO. From 2005 to 2013 Mr Paterson held senior positions at Merck KGaA, most recently as President of Europe, Canada and Australia. Prior to this, Mr Paterson was President of Emerging Markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, Mr Paterson served at Roche Pharmaceuticals where he was most recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. Mr Paterson is an Australian national and resides in Minneapolis, Minnesota, United States of America.
|
Dr Wenyi Gu | Non-Executive Director | Oct 2018 |
Dr Gu currently works as Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland (UQ), where he began his post-doctoral work in 2001. He held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council (NHMRC) to work at Harvard Medical School, Harvard University as a visiting research fellow. Before engaging in nanomedicine (focusing on drug delivery and cancer therapy), he worked on RNAi-based gene therapy for several years at Translation Research Institute (TRI). Dr Gu's research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. Dr Gu is a resident of Brisbane, QLD, Australia.
|
Mr Matthew McDonnell | Chief Financial Officer |
-
|
|
Mr David St Denis | Chief Operating Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Perceptive Life Sciences Master Fund Ltd | 1,840,000 | 11.98% |
Hsbc Custody Nominees (Australia) Limited A/C 2 | 1,043,353 | 6.79% |
Hsbc Custody Nominees (Australia) Limited Gsco Eca | 633,164 | 4.12% |
J P Morgan Nominees Australia Pty Limited | 561,484 | 3.66% |
Citicorp Nominees Pty Limited | 548,442 | 3.57% |
Hunter Capital Advisors P/L | 478,991 | 3.12% |
Hsbc Custody Nominees (Australia) Limited | 382,689 | 2.49% |
Mutual Trust Pty Ltd | 335,689 | 2.19% |
Hsbc Custody Nominees (Australia) Limited Gsi Eda | 322,259 | 2.10% |
Mr Patrick Chew | 314,555 | 2.05% |
Mr Ricky Steven Neumann | 310,774 | 2.02% |
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> | 290,864 | 1.89% |
Bnp Paribas Noms Pty Ltd <Global Markets Drp> | 256,009 | 1.67% |
Evolution Capital Pty Ltd | 247,522 | 1.61% |
Bnp Paribas Noms Pty Ltd <Drp> | 177,132 | 1.15% |
Merrill Lynch (Australia) Nominees Pty Limited | 146,791 | 0.96% |
Amedan Pty Ltd | 138,700 | 0.90% |
Mishtalem Pty Ltd | 134,000 | 0.87% |
Mr David Lamm | 125,000 | 0.81% |
Dr Gary Owen Rooke | 120,000 | 0.78% |